Influence of the Surface Properties of the Bois Carre Seeds Activated Carbon for the Removal of Lead From Aqueous Ssolutions

An activated carbon from Bois carré (Citharexylum Fruticosum L.) seeds was prepared by chemical activation with phosphoric acid. The activated carbon obtained has a surface area of 594 m2/g and a high content of acid groups of 3.44 mmol.g-1. This carbon was studied for the removal of lead from water. Sorption studies were performed at 30 °C at different pH and adsorbent doses, in batch mode. Maximum adsorption occurred at pH 7 for an adsorbent dose of 1g/L. Kinetic studies, at the initial concentration of 150 mg/L of lead, pH 5 and an adsorbent dose of 1 g/L, yielded an equilibrium time of 30 h for this activated carbon. The kinetic data were modelled with the pseudo first order, the pseudo second order and the Bangham models. The pseudo second order model fitted the data well. The sorption rate constant (2.10-3 mol-1.Kg.s-1) and the maximum amount of lead adsorbed are quite good (0.18 mol.kg-1) compared to the data found in literature. Sorption equilibrium studies were conducted in a concentration range of lead from 0 to 150 mg/L, at pH 5, adsorbent dose 1 g/L. In an aqueous lead solution with an initial concentration of 30 mg/L, activated Bois carré seed carbon removed (at equilibrium) 48 % of the heavy metal. The equilibrium data were modelled with the Langmuir and Freundlich equations, of which the latter gave the best fit. The Freundlich constants n (3.76 L.mol-1) and Kf (1.06 mol.kg-1) are in good agreement with literature. The Bois carré seed activated carbon is a very efficient carbon in terms of the metal amount adsorbed per unit of surface area (0. 06 m2 /g). This good result is due to the presence of many active acid sites on the surface of this activated carbon

Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD.

The treatment and management of COPD by inhalation to the lungs has emerged as an attractive alternative route to oral dosing due to higher concentrations of the drug being administered to site of action. In this study, Nanocomposite Microparticles (NCMPs) of microRNA (miR-146a) containing PGA-co-PDL nanoparticles (NPs) for dry powder inhalation were formulated using l-leucine and mannitol. The spray-drying (Buchi B290) process was optimised and used to incorporate NPs into NCMPs using mix of l-leucine and mannitol excipients in different ratios (F1; 100:0% w/w, F2; 75:25% w/w, F3; 50:50% w/w, F4; 25:75% w/w, F5; 0:100% w/w) to investigate yield %, moisture content, aerosolisation performance and miR-146a biological activity. The optimum condition was performed at feed rate 0.5 ml/min, aspirator rate 28 m3/h, atomizing air flow rate 480 L/h, and inlet drying temperature 70 °C which produced highest yield percentage and closest recovered NPs size to original prior spray-drying. The optimum formulation (F4) had a high yield (86.0 ± 15.01%), recovered NPs size after spray-drying 409.7 ± 10.05 nm (initial NPs size 244.8 ± 4.40 nm) and low moisture content (2.02 ± 0.03%). The aerosolisation performance showed high Fine Particle Fraction (FPF) 51.33 ± 2.9%, Emitted Dose (ED) of 81.81 ± 3.0%, and the mass median aerodynamic diameter (MMAD) was ≤5 µm suggesting a deposition in the respirable region of the lungs. The biological activity of miR-146a was preserved after spray-drying process and miR-146a loaded NCMPs produced target genes IRAK1 and TRAF6 silencing. These results indicate the optimal process parameters for the preparation of NCMPs of miR-146a-containing PGA-co-PDL NPs suitable for inhalation in the treatment and management of COPD

Direct lung delivery of a dry powxer formulation, of DTPA with improved aerosolization properties : effect on lung and systemic decorporation of plutonium

International audienceDTPA, an actinide chelating agent, has demonstrated its ability to complex plutonium (Pu) and to facilitate its urinary excretion after internal contamination. This process, known as decorporation is crucial to diminish the burden of Pu in the body. The ability to deliver a chelating agent directly to the alveolar region may increase its local concentration as compared to systemic delivery and therefore increase the extent of decorporation. Second, inhalation offers the potential for needle-free, systemic delivery of small molecules and would be convenient in case of nuclear accident as a first pass emergency treatment. To benefit from the improvement of inhalation technology, we have formulated DTPA into porous particles by spray-drying with dl-Leucine, DPPC and ammonium bicarbonate. The optimized particles possess a volume mean geometric diameter around 4.5 μm and crumpled paper morphology. The in vitro aerodynamic evaluation shows that about 56% of the powder should deposits in the lungs, with about 27% in the alveolar region, an improvement as compared with the micronized powder available with the Spinhaler®. After pulmonary administration to rats contaminated with PuO2, a 3-fold increase of the Pu urinary excretion was observed, but the dissolution of PuO2 in the lungs was not enhanced